vector icon vector icon
Back
Message sent successfully
fugure icon fugure icon
Back to News & Events

ArtiFascia Pivotal NEOART study has been initiated

linkedin facebook twitter email
ArtiFascia Pivotal NEOART study has been initiated

Nurami has announced the initiation of NEOART clinical study to test its Dural repair patch – ArtiFascia®. Multiple leading EU medical centers participate in the study. The enrollment of patients is ongoing.

Related content
Tuesday, 14 Mar 2023
Nurami Medical has been accepted to the In-Ventech Growth Stage Program
Wednesday, 21 Sep 2022
Nurami Medical announces positive results from its brain surgery clinical trial
figure icon

Most popular

Nurami Medical has been accepted to the In-Ventech Growth Stage Program
Tuesday, 14 Mar 2023
Nurami Medical has been accepted to the In-Ventech Growth Stage Program
Nurami Medical announces positive results from its brain surgery clinical trial
Wednesday, 21 Sep 2022
Nurami Medical announces positive results from its brain surgery clinical trial
ArtiFascia® Receives 510K Clearance
Tuesday, 08 Mar 2022
ArtiFascia® Receives 510K Clearance
Nurami welcomes Peter Stebbins, its new Executive Chair of the Board
Friday, 04 Feb 2022
Nurami welcomes Peter Stebbins, its new Executive Chair of the Board

Contact us

Israel
USA
Nurami Medical Ltd. HQ
Israel
Nurami Medical Ltd. HQ
36 Ha-Namal St., Haifa, Israel
Nurami Medical Ltd. HQ
USA
Nurami Medical Inc.
2436 Emrick Boulevard,
Bethlehem, PA 18020, USA
Message sent successfully
Skip to content